

# Cindy Shin-Yi Lin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8320280/cindy-shin-yi-lin-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75  
papers

2,801  
citations

27  
h-index

51  
g-index

82  
ext. papers

3,259  
ext. citations

7.9  
avg, IF

4.83  
L-index

#	Paper	IF	Citations
75	Altered sensory nerve excitability in fibromyalgia. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> , 120, 1611-1619	3.2	1
74	Differences in nerve excitability properties across upper limb sensory and motor axons.. <i>Clinical Neurophysiology</i> , <b>2021</b> , 136, 138-149	4.3	0
73	Immune-mediated axonal dysfunction in seropositive and seronegative primary Sjögren's syndrome. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 819-828	5.3	2
72	Early sensory neurophysiological changes in prediabetes. <i>Journal of Diabetes Investigation</i> , <b>2020</b> , 11, 458-465	3.9	6
71	Measurement of axonal excitability: Consensus guidelines. <i>Clinical Neurophysiology</i> , <b>2020</b> , 131, 308-323	4.3	31
70	Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> ,	5.5	8
69	Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 898	4.1	21
68	Elucidating Unique Axonal Dysfunction Between Nitrous Oxide Abuse and Vitamin B12 Deficiency. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 704	4.1	14
67	009 Axonal excitability properties in dravet syndrome reflect effect of loss of sodium channels. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, A4.1-A4	5.5	
66	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. <i>Muscle and Nerve</i> , <b>2018</b> , 57, 615-621	3.4	2
65	Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. <i>Journal of Neuroimmunology</i> , <b>2017</b> , 309, 41-46	3.5	38
64	Burning pain: axonal dysfunction in erythromelalgia. <i>Pain</i> , <b>2017</b> , 158, 900-911	8	8
63	The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity. <i>Diabetes</i> , <b>2017</b> , 66, 1661-1670	0.9	16
62	Cardiometabolic health and risk of amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , <b>2017</b> , 56, 721-725	3.4	4
61	Uncovering sensory axonal dysfunction in asymptomatic type 2 diabetic neuropathy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0171223	3.7	19
60	Immune dysregulation in patients with carpal tunnel syndrome. <i>Scientific Reports</i> , <b>2017</b> , 7, 8218	4.9	8
59	Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial. <i>Clinical Neurophysiology</i> , <b>2017</b> , 128, 93-99	4.3	6

58	Exploring the Evolution of Cortical Excitability Following Acute Stroke. <i>Neurorehabilitation and Neural Repair</i> , <b>2016</b> , 30, 244-57	4.7	29
57	In vivo evidence of reduced nodal and paranodal conductances in type 1 diabetes. <i>Clinical Neurophysiology</i> , <b>2016</b> , 127, 1700-1706	4.3	15
56	Effect of fampridine on axonal excitability in multiple sclerosis. <i>Clinical Neurophysiology</i> , <b>2016</b> , 127, 2636-42	4.4	8
55	Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , <b>2015</b> , 262, 1424-32	5.5	31
54	Short-term peripheral nerve stimulation ameliorates axonal dysfunction after spinal cord injury. <i>Journal of Neurophysiology</i> , <b>2015</b> , 113, 3209-18	3.2	18
53	Segmental motoneuronal dysfunction is a feature of amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , <b>2015</b> , 126, 828-36	4.3	19
52	Sensory axonal dysfunction in cervical radiculopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2015</b> , 86, 640-5	5.5	6
51	Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. <i>EBioMedicine</i> , <b>2015</b> , 2, 1916-22	8.8	20
50	Reply: biomarkers of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. <i>Brain</i> , <b>2015</b> , 138, e336	11.2	
49	Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2015</b> , 86, 973-85	5.5	243
48	Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2015</b> , 31, 175-82	7.5	13
47	Guillain-Barré syndrome in Asia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 907-13	5.5	40
46	Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. <i>Brain</i> , <b>2014</b> , 137, 2155-63	11.2	23
45	Transsynaptic changes evident in peripheral axonal function after acute cerebellar infarct. <i>Cerebellum</i> , <b>2014</b> , 13, 669-76	4.3	5
44	Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. <i>Muscle and Nerve</i> , <b>2014</b> , 49, 858-65	3.4	10
43	Axonal dysfunction with voltage gated potassium channel complex antibodies. <i>Experimental Neurology</i> , <b>2014</b> , 261, 337-42	5.7	11
42	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. <i>BMC Cancer</i> , <b>2014</b> , 14, 993	4.8	17
41	Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. <i>Clinical Neurophysiology</i> , <b>2014</b> , 125, 179-85	4.3	33

40	Motor cortex excitability in acute cerebellar infarct. <i>Cerebellum</i> , <b>2013</b> , 12, 826-34	4.3	12
39	Porphyric neuropathy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2013</b> , 115, 613-27	3	11
38	Controversies and priorities in amyotrophic lateral sclerosis. <i>Lancet Neurology, The</i> , <b>2013</b> , 12, 310-22	24.1	377
37	Axonal dysfunction prior to neuropathy onset in type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2013</b> , 29, 53-9	7.5	27
36	Longitudinal plasticity across the neural axis in acute stroke. <i>Neurorehabilitation and Neural Repair</i> , <b>2013</b> , 27, 219-29	4.7	30
35	Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. <i>Journal of Physiology</i> , <b>2013</b> , 591, 273-86	3.9	19
34	Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. <i>Journal of the Peripheral Nervous System</i> , <b>2013</b> , 18, 275-96	4.7	39
33	Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. <i>Muscle and Nerve</i> , <b>2013</b> , 48, 93-9	3.4	19
32	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. <i>Brain</i> , <b>2013</b> , 136, 1361-70	11.2	102
31	Chemotherapy-induced peripheral neurotoxicity: a critical analysis. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2013</b> , 63, 419-37	220.7	410
30	Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. <i>American Journal of Transplantation</i> , <b>2013</b> , 13, 2426-32	8.7	53
29	Effects of axonal ion channel dysfunction on quality of life in type 2 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 1272-7	14.6	28
28	Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e59055	3.7	15
27	Nerve Excitability: A Clinical Translation <b>2012</b> , 345-365		6
26	Impaired energy-dependent processes underlie acute lead neuropathy. <i>Muscle and Nerve</i> , <b>2012</b> , 46, 957-64	6.1	6
25	Impact of oxaliplatin-induced neuropathy: a patient perspective. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 2959-67	3.9	76
24	Differences in excitability between median and superficial radial sensory axons. <i>Clinical Neurophysiology</i> , <b>2012</b> , 123, 1440-5	4.3	3
23	Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , <b>2012</b> , 123, 2460-7	4.3	35

22	Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. <i>Diabetes</i> , <b>2012</b> , 61, 1592-8	0.9	42
21	Nerve excitability assessment in chemotherapy-induced neurotoxicity. <i>Journal of Visualized Experiments</i> , <b>2012</b> ,	1.6	15
20	Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. <i>Clinical Neurophysiology</i> , <b>2011</b> , 122, 194-8	4.3	6
19	Purple pigments: the pathophysiology of acute porphyric neuropathy. <i>Clinical Neurophysiology</i> , <b>2011</b> , 122, 2336-44	4.3	34
18	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. <i>Experimental Neurology</i> , <b>2011</b> , 227, 120-7	5.7	14
17	Activity-dependent conduction failure: molecular insights. <i>Journal of the Peripheral Nervous System</i> , <b>2011</b> , 16, 159-68	4.7	11
16	The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 1189-90; author reply 1191-2	3.5	2
15	Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. <i>Muscle and Nerve</i> , <b>2011</b> , 43, 367-74	3.4	52
14	Nerve compression, membrane excitability, and symptoms of carpal tunnel syndrome. <i>Muscle and Nerve</i> , <b>2011</b> , 44, 402-9	3.4	11
13	The effects of large artery ischemia and subsequent recanalization on nerve excitability. <i>Muscle and Nerve</i> , <b>2011</b> , 44, 841-2	3.4	7
12	Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. <i>Archives of Neurology</i> , <b>2011</b> , 68, 862-9		46
11	Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. <i>Oncologist</i> , <b>2011</b> , 16, 708-16	5.7	148
10	Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e553-4; author reply e555-6	2.2	8
9	Adaptation of motor function after spinal cord injury: novel insights into spinal shock. <i>Brain</i> , <b>2011</b> , 134, 495-505	11.2	26
8	Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. <i>Brain</i> , <b>2011</b> , 134, 3185-97	11.2	25
7	Dose effects of oxaliplatin on persistent and transient Na <sup>+</sup> conductances and the development of neurotoxicity. <i>PLoS ONE</i> , <b>2011</b> , 6, e18469	3.7	57
6	Changes in human sensory axonal excitability induced by focal nerve compression. <i>Journal of Physiology</i> , <b>2010</b> , 588, 1737-45	3.9	19
5	Acute, reversible axonal energy failure during stroke-like episodes in MELAS. <i>Pediatrics</i> , <b>2010</b> , 126, e734-9	4	14

4	Axonal changes in spinal cord injured patients distal to the site of injury. <i>Brain</i> , <b>2007</b> , 130, 985-94	11.2	76
3	After-effects of near-threshold stimulation in single human motor axons. <i>Journal of Physiology</i> , <b>2005</b> , 564, 931-40	3.9	30
2	Variations in excitability of single human motor axons, related to stochastic properties of nodal sodium channels. <i>Journal of Physiology</i> , <b>2004</b> , 559, 953-64	3.9	34
1	Clinical evaluation of excitability measures in sensory nerve. <i>Muscle and Nerve</i> , <b>2001</b> , 24, 883-92	3.4	128